Anti-B7-H3 ADC Combined with ATR/ATM Inhibitor for Cancer Treatment
Summary
The USPTO published patent application US20260091123A1 by Daiichi Sankyo Company Limited covering a pharmaceutical composition and method of treatment combining an anti-B7-H3 antibody-drug conjugate with an ATR inhibitor or ATM inhibitor for cancer therapy. The application claims the drug-linker conjugate structure and treatment methods. Filing date was October 9, 2025.
What changed
Daiichi Sankyo filed USPTO patent application US20260091123A1 for a combination therapy comprising an anti-B7-H3 antibody-drug conjugate linked via thioether bond, used together with either an ATR inhibitor or ATM inhibitor for treating cancer (classified A61P 35/00). The composition claims specific CPC classifications including A61K 47/6849, A61K 31/4745, and A61K 47/65. The application names inventors Len Katsumata, Jun Hasegawa, and Chiharu Hattori.
This patent publication does not create compliance obligations for pharmaceutical companies. Companies developing similar ADC or ATR/ATM inhibitor combination therapies should review the patent claims for potential freedom-to-operate concerns. The application provides public notice of the claimed invention and its scope, which may inform R&D planning and competitive landscape assessment.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMBINATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR OR ATM INHIBITOR
Application US20260091123A1 Kind: A1 Apr 02, 2026
Assignee
DAIICHI SANKYO COMPANY, LIMITED
Inventors
Len KATSUMATA, Jun HASEGAWA, Chiharu HATTORI
Abstract
In some aspects, an object of the present invention is to provide a pharmaceutical composition and a method of treatment comprising administering a specific anti-B7-H3 antibody-drug conjugate in combination with an ATR inhibitor or an ATM inhibitor. Solution: In some aspects, provided is a pharmaceutical composition and a method of treatment, comprising administering an antibody-drug conjugate, in which a drug-linker represented by the following formula: wherein A represents a connecting position to an anti-B7-H3 antibody, and the anti-B7-H3 antibody are conjugated via a thioether bond, in combination with an ATR inhibitor or an ATM inhibitor.
CPC Classifications
A61K 47/6849 A61K 31/4745 A61K 31/5377 A61K 47/545 A61K 47/65 A61K 47/68037 A61P 35/00
Filing Date
2025-10-09
Application No.
19353836
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.